The 6th China International Import Expo (CIIE) held in Shanghai this week has been a platform for multiple companies to announce their strategic partnerships in China. Among the notable participants are Danaher (NYSE: DHR), Boehringer-Ingelheim (BI), Merck Sharp & Dohme (MSD, NYSE: MRK), Johnson & Johnson (J&J, NYSE: JNJ), BeiGene (NASDAQ: BGNE), and Fosun Pharma (SHA: 600196), all of which have revealed significant collaborations.
Danaher’s Western China Center
Danaher has plans to jointly establish its Western China center with local firm Zein Biotechnology in Chongqing. This move is set to strengthen Danaher’s presence in the region and enhance its service capabilities in China.
Boehringer-Ingelheim’s Collaboration with NMI Pharmaceutical
BI will provide process development and manufacturing services to Guangzhou-based NMI Pharmaceutical, particularly in relation to the latter’s inflammatory drugs. This partnership is aimed at boosting the development and production of important medications in China.
MSD and Peking University Joint Laboratory
MSD is set to establish a joint laboratory for infectious disease prevention and control technology with Peking University. The collaboration is designed to promote the integration of industry, academia, and research, and to explore long-term cooperation projects in public health technology innovation, real-world research in key disease fields, research transformation, and public health talent development.
Johnson & Johnson’s Medical Device Procurement Deals
J&J has struck significant medical device procurement deals with local companies Jointown Medical Devices Group, China Resources Biopharma, and Sinopharm, with investments of USD 500 million, USD 100 million, and USD 400 million respectively. These deals cover areas such as surgery, orthopedics, and intervention solutions.
BeiGene and Cowell Health Cancer Management System
BeiGene has joined forces with Cowell Health to establish a comprehensive cancer patient full lifecycle management system. This collaboration aims to improve cancer care and management for patients in China.
Fosun Pharma and Shanghai Zhangjiang Group Agreement
Finally, Fosun Pharma and Shanghai Zhangjiang Group have agreed to delve deeper into innovation leadership, industrial cooperation, and talent attraction and cohesion. This partnership is set to enhance the innovation capabilities and industry collaboration in the Chinese pharmaceutical sector.- Flcube.com
